ANN ARBOR – Accuri Cytometers said Monday the company has completed a $6 million Series E preferred stock financing. The financing included current
investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences,
Flagship Ventures and the InvestMichigan! Program co-managed by Credit
Suisse.
Accuri plans to use the proceeds from the Series E financing to
support expansion of the Accuri C6 Flow Cytometer System into the clinical
in vitro diagnostics (IVD) market. The Accuri C6 is a revolutionary product
designed to bring the power of flow cytometry analysis to every life
sciences and biomedical laboratory. Explicitly designed for routine use by
scientists in their own labs, Accuri’s flow cytometer is a full-featured
bench-top cell analysis system that provides capabilities similar to
industry-leading flow cytometers in a much more user-friendly format and at
a fraction of the cost.
“Fueled by our continued sales growth in the U.S. and Europe and our
recent expansion into international markets in Asia and South America,
Accuri is now one of the fastest growing cell analysis companies
worldwide,” said Jeffrey Williams, President and CEO of Accuri. “This
financing round will enable us to respond to a rising number of requests
for an Accuri flow cytometer for clinical diagnostic applications,
providing the same benefits of high performance, cost-effectiveness and
ease-of-use experienced by our life science research customers.”
Accuri is currently implementing an ISO13485 Quality System in
preparation for the planned European launch of the Accuri C6 Flow Cytometer
with CE-IVD mark certification for clinical use, to be followed by a 510
(K) regulatory submission to the Food & Drug Administration seeking
clearance to market the Accuri C6 Flow Cytometer for clinical IVD
applications in the U.S.
For more information, click on Accuricytometers.Com
a>>
